Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Current Assets (2018 - 2025)

BioNexus Gene Lab's Current Assets history spans 8 years, with the latest figure at $5.6 million for Q3 2025.

  • For Q3 2025, Current Assets fell 20.07% year-over-year to $5.6 million; the TTM value through Sep 2025 reached $5.6 million, down 20.07%, while the annual FY2024 figure was $7.4 million, 7.66% down from the prior year.
  • Current Assets for Q3 2025 was $5.6 million at BioNexus Gene Lab, down from $6.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $8.3 million in Q3 2023 and bottomed at $5.2 million in Q2 2023.
  • The 5-year median for Current Assets is $7.0 million (2024), against an average of $6.8 million.
  • The largest annual shift saw Current Assets soared 927.78% in 2021 before it decreased 26.93% in 2022.
  • A 5-year view of Current Assets shows it stood at $7.1 million in 2021, then dropped by 15.78% to $6.0 million in 2022, then skyrocketed by 33.63% to $8.0 million in 2023, then fell by 7.66% to $7.4 million in 2024, then fell by 24.27% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Current Assets are $5.6 million (Q3 2025), $6.4 million (Q2 2025), and $6.5 million (Q1 2025).